Hims & Hers Health (NYSE:HIMS) Stock Price Up 9.1% – Here’s What Happened

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price rose 9.1% during trading on Monday . The stock traded as high as $20.98 and last traded at $21.2050. Approximately 10,095,123 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 32,452,229 shares. The stock had previously closed at $19.43.

Analyst Ratings Changes

HIMS has been the topic of a number of research analyst reports. TD Cowen decreased their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, March 27th. Evercore set a $24.00 target price on Hims & Hers Health in a research report on Tuesday, February 24th. Citigroup upgraded Hims & Hers Health from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $13.25 to $24.00 in a research report on Tuesday, March 10th. Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research report on Monday, March 9th. Finally, Bank of America upgraded Hims & Hers Health from an “underperform” rating to a “neutral” rating and boosted their target price for the stock from $12.50 to $23.00 in a research report on Tuesday, March 10th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $31.71.

Hims & Hers Health Stock Up 9.4%

The company has a 50 day simple moving average of $19.72 and a two-hundred day simple moving average of $33.25. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $4.84 billion, a P/E ratio of 41.68, a PEG ratio of 1.85 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same period in the previous year, the firm posted $0.11 earnings per share. The firm’s revenue for the quarter was up 28.4% on a year-over-year basis. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the sale, the insider directly owned 8,752 shares of the company’s stock, valued at $216,086.88. The trade was a 38.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 4,812 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $118,808.28. Following the sale, the insider directly owned 308,831 shares in the company, valued at $7,625,037.39. The trade was a 1.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 129,889 shares of company stock valued at $3,230,986. Insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Quent Capital LLC bought a new position in shares of Hims & Hers Health during the third quarter valued at approximately $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the third quarter valued at approximately $28,000. Hilltop National Bank bought a new position in shares of Hims & Hers Health during the third quarter valued at approximately $35,000. Silicon Valley Capital Partners bought a new position in shares of Hims & Hers Health during the third quarter valued at approximately $48,000. Finally, Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $28,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.